Business, energy, technology, markets and global industry news from Business News Today

Corcept Therapeutics Incorporated

PharmaDeviceNews Corcept Therapeutics Incorporated
Representative image: Corcept Therapeutics has resubmitted the relacorilant New Drug Application for Cushing’s syndrome, reopening FDA scrutiny of efficacy, trial design and liver safety evidence.
Pharma & Biotech

Corcept revives its Cushing’s bid with relacorilant, yet the hardest evidence gap remains

Read how Corcept’s relacorilant NDA resubmission could reshape Cushing’s treatment while efficacy and liver safety questions remain.

Read More
Representative image of clinical diabetes data review, highlighting Corcept’s Korlym findings in hypercortisolism-linked type 2 diabetes and GLP-1 treatment outcomes.
Pharma & Biotech

Corcept’s Korlym data put hypercortisolism back in focus for cardiometabolic disease

Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.

Read More
Pharma & Biotech

Why Corcept Therapeutics now faces a bigger execution test after Lifyorli’s ROSELLA success

Corcept Therapeutics’ Lifyorli showed strong survival benefit in ovarian cancer. Read what the ROSELLA data could change for clinicians and payers.

Read More
Corcept secures a pivotal ovarian cancer win as Lifyorli validates glucocorticoid receptor blockade in oncology
Pharma & Biotech

Can Corcept’s Lifyorli become a real new standard in platinum-resistant ovarian cancer after FDA approval?

Corcept’s Lifyorli won FDA approval in platinum-resistant ovarian cancer. Read what the survival data could change for clinicians, rivals, and regulators.

Read More
Pharma & Biotech

Corcept’s relacorilant CRL leaves endocrinology ambitions in limbo as oncology pivot takes center stage

Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.

Read More